EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Open Access · CC BY-NC-ND 4.0

Pharmacokinetics and Safety of Atogepant Co‐administered with Quinidine Gluconate in Healthy Participants: A Phase 1, Open‐Label, Drug‐Drug Interaction Study

Ramesh Boinpally, Lisa Borbridge, Veronica Wangsadipura

Clinical Pharmacology in Drug Development · 2024

DOI: 10.1002/cpdd.1407 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Clinical Pharmacology in Drug Development, 2024. Verfasst von Ramesh Boinpally und 2 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology, AbbVie, North Chicago, IL, USA. Hauptthemen laut MEDLINE: Drug Interactions, Quinidine, Healthy Volunteers. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: AbbVie, Inc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Atogepant, an oral calcitonin gene‐related peptide receptor antagonist, is approved for the preventive treatment of migraine. Atogepant is a substrate of P‐glycoprotein (P‐gp), breast cancer resistance protein, organic anion transporting polypeptide transporters, and cytochrome P450 (CYP)3A4 and 2D6. Quinidine is a strong P‐gp and CYP2D6 inhibitor. A phase 1 open‐label study evaluated the effect of P‐gp and CYP2D6 inhibition by quinidine on the pharmacokinetics of atogepant, and the safety and tolerability of atogepant and quinidine gluconate (QG) when co‐administered and when given alone in 33 healthy adults. There was no significant change in the atogepant maximum plasma concentration with QG co‐administration. The overall systemic exposure, the area under the plasma concentration‐time curve (from time 0 to time t or to infinity), of atogepant increased by 25% when co‐administered with QG. However, such an increase was not considered clinically relevant. Atogepant did not alter the mean plasma concentration of quinidine at steady state. The incidence of treatment‐emergent adverse events (TEAEs) was highest when QG was administered alone (42.4%), which was primarily due to QT prolongation. Most TEAEs reported were mild in severity and resolved within 1‐2 days. Co‐administration of atogepant with QG did not result in any unexpected tolerability findings in this phase 1 study in healthy participants. The increase in atogepant exposure during QG co‐administration could be due to inhibition of CYP2D6 (a minor contributor to atogepant clearance) as well as inhibition of P‐gp.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug InteractionsQuinidineHealthy VolunteersHumansAdultMaleFemaleYoung AdultMiddle AgedArea Under CurveATP Binding Cassette Transporter, Subfamily B, Member 1Cytochrome P-450 CYP2D6 Inhibitors

Stichwörter der Autor:innen

CGRP receptor antagonistCYP2D6P‐gpatogepantdrug‐drug interactionsmigrainequinidine

Substanzen

QuinidineATP Binding Cassette Transporter, Subfamily B, Member 1Cytochrome P-450 CYP2D6 Inhibitors

Autor:innen und Institutionen

  • Clinical Pharmacology, AbbVie, North Chicago, IL, USA.
  • Bioanalysis, AbbVie, Irvine, CA, USA.
  • Data and Statistical Sciences, AbbVie, Irvine, CA, USA.

Förderung

  • AbbVie, Inc.

Zitieren

APA

Boinpally, R., Borbridge, L., & Wangsadipura, V. (2024). Pharmacokinetics and Safety of Atogepant Co‐administered with Quinidine Gluconate in Healthy Participants: A Phase 1, Open‐Label, Drug‐Drug Interaction Study. Clinical Pharmacology in Drug Development. https://doi.org/10.1002/cpdd.1407

Vancouver

Boinpally R, Borbridge L, Wangsadipura V. Pharmacokinetics and Safety of Atogepant Co‐administered with Quinidine Gluconate in Healthy Participants: A Phase 1, Open‐Label, Drug‐Drug Interaction Study. Clinical Pharmacology in Drug Development. 2024. doi:10.1002/cpdd.1407

BibTeX
@article{Boinpally2024,
  author = {Boinpally, Ramesh and Borbridge, Lisa and Wangsadipura, Veronica},
  title = {Pharmacokinetics and Safety of Atogepant Co‐administered with Quinidine Gluconate in Healthy Participants: A Phase 1, Open‐Label, Drug‐Drug Interaction Study},
  journal = {Clinical Pharmacology in Drug Development},
  year = {2024},
  doi = {10.1002/cpdd.1407}
}
Kostenlos starten →